CK 0808
Alternative Names: CK-0808Latest Information Update: 27 Oct 2022
At a glance
- Originator Cellenkos
- Class T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lupus nephritis
Most Recent Events
- 11 Oct 2022 Preclinical trials in Lupus nephritis in USA (Parenteral) (Cellenkos website, October 2022)